Benzinga Pro data, Onconova Therapeutics (NASDAQ:ONTX) reported Q2 sales of $57.00 thousand. Earnings fell to a loss of $4.64 million, resulting in a 13.35% decrease from last quarter.
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
October 8, 7:31 AM
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 7)
The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout
October 5, 8:01 AM
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 4)
September 30, 11:21 AM
Onconova Therapeutics (NASDAQ:ONTX) brought in sales totaling $57.00 thousand during Q2 according to data provided by Benzinga Pro. However, earnings decreased 13.35%, resulting in a loss of $4.64 million.
September 28, 4:06 PM
Onconova Therapeutics, Inc. (NASDAQ:ONTX) ("Onconova"), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced the
September 24, 3:06 PM
Toward the end of trading Friday, the Dow traded up 0.12% to 34,805 while the NASDAQ fell 0.13% to 15,033.02. The S&P also rose, gaining 0.12% to 4,454.25.
Mid-Day Market Update: Aehr Test Systems Surges Following Q1 Results; Onconova Therapeutics Shares Slide
September 24, 12:13 PM
Midway through trading Friday, the Dow traded down 0.03% to 34,753.87 while the NASDAQ fell 0.45% to 14,984.38. The S&P also fell, dropping 0.10% to 4,444.74.